Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
142
resultados
Última actualización
21/06/2025 [08:39:00]
Resultados 75 a 100 de 142
Resumen de: US2025160703A1
A system for reducing sensor variability includes a sensor configured to generate real-time data relating to glucose sensitivity. The system causes performance of accessing the real-time data from the sensor relating to glucose sensitivity and inputting the real-time data into a machine learning model. The system also causes performance of estimating by the machine learning model an expected glucose sensitivity based on the real-time data and correcting the glucose sensitivity based on the expected glucose sensitivity.
Resumen de: US2025160695A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: US2025160692A1
Polyesteramide (PEA) copolymers are disclosed, having structures that include repeating units that contain various monomer residues characterized herein and present in the repeating units at defined ranges of molar equivalents. These copolymers can possess a number of important advantages for providing longer performing glucose sensors and/or for simplifying their design. For example, in vivo modeling has confirmed that these polymers exhibit both decreased collagen deposition and increased neovascularization (angiogenesis). Additional testing has demonstrated favorable oxygen and glucose transport capabilities, as well as other relevant properties.
Resumen de: US2025160694A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: US2025160696A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: US2025160642A1
In some example embodiments, there is provided a method, which includes sending a message to a server, wherein the message includes a request for a share code to enable another user to access, via a first computer, analyte data obtained from a host-patient associated with a receiver and/or an analyte report for the host-patient associated with the receiver; receiving, in response to the sending, the share code generated by the server, wherein the share code comprises a checksum portion, a password portion, and an identifier portion indicative of the host-patient; generating a user interface view including the share code; and displaying the user interface view including the share code, wherein the share code enables the other user to access, via the first computer, the analyte data and/or the analyte report. Related systems, methods, and articles of manufacture are also disclosed.
Resumen de: US2025161567A1
Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated.
Resumen de: US2025161568A1
Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, a controller module, and optionally a single point glucose monitor are provided. Integration may be manual, semi-automated and/or fully automated.
Resumen de: US2025160697A1
Certain aspects of the present disclosure relate to a monitoring system comprising a continuous analyte sensor configured to generate analyte measurements associated with analyte levels of a patient, and a sensor electronics module coupled to the continuous analyte sensor and configured to receive and process the analyte measurements.
Resumen de: US2025161566A1
Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated.
Resumen de: US2025166855A1
Presented herein is a handheld analyte measurement device. The analyte measurement device includes one or more software applications to help the user manager their diabetes. Embodiments and descriptions of the various applications are provided below in conjunction with the handheld analyte measurement device.
Resumen de: WO2025106335A1
Techniques for generating and modifying user interfaces for displaying glucose sensor data are disclosed. Initial or first sensor data is displayed with a first formatting until it is dynamically changed to a second formatting that de-emphasizes the data while new sensor data is concurrently displayed with the first formatting to emphasize the new sensor data relative to the older / first sensor data.
Resumen de: US2025166814A1
Medical devices, systems, and methods related thereto a glucose monitoring system having a first display unit in data communication with a skin-mounted assembly, the skin-mounted assembly including an in vivo sensor and a transmitter. The first display unit and a second display unit are in data communication with a data management system. The first display unit comprises memory that grants a first user first access level rights and the second display unit comprises memory that grants a second individual second access level rights.
Resumen de: US2025166776A1
Disclosed herein are techniques related to determining medical parameters. In some embodiments, the techniques involve: obtaining a metric of insulin dosage for a patient; and determining at least one carbohydrate-to-insulin ratio for the patient based at least in part on a model and using the obtained metric of insulin dosage for the patient, wherein parameters of the model were determined based on data associated with a population of patients.
Resumen de: WO2025106280A1
Techniques are provided for dynamically managing wireless communications of glucose monitoring systems. The systems dynamically adjust the communication session intervals based on various dynamic conditions. Some systems are also configured with an antenna positioned on an opposing side of a chip from other sensor electronics and/or outside of an encasing of potting material to enhance the signaling functionality of the antenna.
Resumen de: EP4557303A1
Disclosed herein are techniques related to determining medical parameters. In some embodiments, the techniques involve: obtaining a metric of insulin dosage for a patient; and determining at least one carbohydrate-to-insulin ratio for the patient based at least in part on a model and using the obtained metric of insulin dosage for the patient, wherein parameters of the model were determined based on data associated with a population of patients.
Resumen de: EP4555927A1
Techniques disclosed herein relate to glucose level measurement and/or management. In some embodiments, the techniques involve obtaining in vivo characteristics of a glucose sensor predicted using fabrication process measurement data associated with the glucose sensor, the in vivo characteristics including an in vivo sensitivity, an in vivo intercept, or a combination thereof; receiving sensor measurement data measured by the glucose sensor, the sensor measurement data including sensor current (Isig), counter voltage (Vcntr), electrochemical impedance spectroscopy (EIS) data, an age of the glucose sensor, or a combination thereof; and estimating a sensor glucose (SG) value using an SG model, wherein input parameters of the SG model include the in vivo characteristics of the glucose sensor and the sensor measurement data, and the SG value is an output of the SG model.
Resumen de: EP4555928A1
A system for reducing sensor variability includes a sensor configured to generate real-time data relating to glucose sensitivity. The system causes performance of accessing the real-time data from the sensor relating to glucose sensitivity and inputting the real-time data into a machine learning model. The system also causes performance of estimating by the machine learning model an expected glucose sensitivity based on the real-time data and correcting the glucose sensitivity based on the expected glucose sensitivity.
Resumen de: WO2024012479A1
Devices, systems and methods for blood glucose monitoring. The device includes a light emitter, configured to emit light signals; a light receiver, configured to receive the reflected light signal; a controller, configured to operatively connect with the light emitter and the light receiver; and an enclosure. The light signal comprises a first light signal having a first wavelength of about 940nm, a second light signal having a second wavelength of about 1350nm, and/or a third light signal having a third wavelength of about 1500nm, wherein the controller comprises an operating module, and further comprises or operatively connects with a data processing system comprising a machine learning module that analyzes the data signal to generate an output data. The devices, systems and methods are non-invasive and monitor blood glucose levels in real time with high accuracy.
Resumen de: US2025152053A1
A glucose measurement device comprising a light emitting device comprising an SWIR phosphor having emission wavelengths in the range of 1600-2200 nm, the SWIR phosphor comprising a structurally disordered garnet material, a sensitizer ion, and at least one rare earth emitter ion, and a infrared light detector arranged to detect the intensity of short wavelength infrared light emitted by the light emitting device and reflected by a sample. The emission spectra provided by the light emitting device having a high temperature stability at infrared absorption minima and maxima wavelengths of glucose in tissue.
Resumen de: US2025152054A1
Various embodiments of a user-wearable device can comprise a frame configured to mount on a user. The device can include a display attached to the frame and configured to direct virtual images to an eye of the user. The device can also include a light source configured to provide polarized light to the eye of the user and that the polarized light is configured to reflect from the eye of the user. The device can further include a light analyzer configured to determine a polarization angle rotation of the reflected light from the eye of the user such that a glucose level of the user can be determined based at least in part on the polarization angle rotation of the reflected light.
Resumen de: US2025152051A1
This application provides a blood glucose assessment method, an electronic device, and a computer-readable storage medium. The method is applied to a wearable device, and includes: collecting vital sign data of a user in a first cycle of blood glucose assessment; performing blood glucose assessment on the user based on valid vital sign data in the vital sign data, to obtain a blood glucose assessment result corresponding to the first cycle; displaying the blood glucose assessment result corresponding to the first cycle; and automatically starting a next cycle of the blood glucose assessment. According to the technical solutions of this application, blood glucose assessment can be periodically and automatically performed, helping reduce operation complexity for the user.
Resumen de: AU2023373672A1
Invasive glucose sensors and noninvasive glucose sensors may be used in conjunction to improve glucose management for a user. The rate of change (ROC) of glucose levels from a noninvasive glucose sensor may be used rather than or in conjunction with a glucose level of the user from a CGM. A basal insulin delivery rate to the user may be adjusted responsive to the ROC glucose level data from the noninvasive sensor. The glucose level ROC from a noninvasive glucose sensor may be used to predict future glucose level ROCs of the user between operational cycles of an insulin delivery device and/or to identify possible hypoglycemic or hyperglycemic events. These predicted future glucose level ROCs may be used in a cost function of the control system of the insulin delivery device to select basal insulin delivery doses. Glucose level readings may be used to calibrate a noninvasive glucose level sensor.
Resumen de: WO2025099153A1
The invention concerns a method for determining a substance concentration in a sample comprising liquid containing particles, in particular glucose in blood, wherein a refractive index of the liquid is dependent on a concentration of the substance dissolved therein and a density of particles in the liquid is substantially constant. The method comprises obtaining a PPG first signal during a first time period and estimating at last a portion of a noise spectrum from the first obtained signal in particular the frequency domain. At least a portion of the noise spectrum is used to derive the substance concentration or a change in the substance concentration.
Nº publicación: WO2025099149A1 15/05/2025
Solicitante:
AMS OSRAM AG [AT]
AMS-OSRAM AG
Resumen de: WO2025099149A1
The invention concerns a method for determining a substance concentration in a sample comprising liquid containing particles, in particular glucose in blood, wherein a refractive index of the liquid is dependent on a concentration of the substance dissolved therein and a density of particles in the liquid is substantially constant. The method comprises obtaining a PPG first signal during a first time period and estimating a set of complex coefficients from the first obtained signal. The phase difference is determined from those coefficient or a subset thereof and subsequently used to derive the substance concentration or a change in the substance concentration.
BOPI
Sede Electrónica
